Journal Mobile Options
Table of Contents
Vol. 35, Suppl. 1, 2012
Issue release date: February 2012
Add to my selection Citation Download
Onkologie 2012;35(suppl 1):21–27
(DOI:10.1159/000334958)
Paper

Targeted Therapy of Soft Tissue Sarcomas

Wardelmann E.a · Chemnitz J.M.b · Wendtner C.b,c
aInstitute of Pathology, bDepartment I of Internal Medicine, University Hospital Cologne, cDepartment of Hematology, Oncology, Immunology, Palliative Care, Infectious Diseases and Tropical Medicine, Klinikum Schwabing, Munich, Germany Onkologie 2012;35(suppl 1):21–27 (DOI:10.1159/000334958)

Abstract

Soft tissue sarcomas (STS) are rare mesenchymal cancers with a heterogeneous histology. In terms of oncogenesis, sarcomas may be differentiated into diseases with defined molecular events and sarcomas presenting with complex karyotypes lacking identifiable specific genetic changes or expression profile signatures. The former subtype is amenable to therapy with targeted drugs, especially if the tumor carries a consistent causal mutation occurring early in the disease development. While targeted therapy based on tyrosine kinase inhibition such as imatinib and second generation tyrosine kinase inhibitors plays an important role in the treatment of gastrointestinal stromal tumors (GIST), some progress was also achieved in non-GIST sarcomas. Targeting the PI3 kinase/Akt pathway has been shown to be clinically promising in a diversity of different sarcoma subtypes, and inhibition of the vascular endothelial growth factor (VEGF)/VEGF receptor pathway is of special interest in vascular sarcoma subtypes. MDM2 and p53 seem to be interesting targets for STS, but their role has yet to be defined in further clinical trials. Modification of epigenetic mechanisms, especially deacetylation, might be crucial in other STS subtypes such as translocation-associated entities, but its role has yet to be clinically confirmed. Inclusion of patients in controlled clinical trials combined with a translational research platform is critical for further progress.

 goto top of outline Author Contacts

Prof. Dr. Clemens-Martin Wendtner, Klinik für Hämatologie, Onkologie, Immunologie, Palliativmedizin, Infektiologie und Tropenmedizin, Klinikum Schwabing, Kölner Platz 1, 80804 München, Germany, Tel. +49 089 3068-2228, Fax -3912, clemens.wendtner@klinikum-muenchen.de


 goto top of outline Article Information

Published online: January 20, 2012
Number of Print Pages : 7


 goto top of outline Publication Details

Onkologie (International Journal for Cancer Research and Treatment)

Vol. 35, No. Suppl. 1, Year 2012 (Cover Date: February 2012)

Journal Editor: Schmoll H.-J. (Halle/Saale), Hallek M. (Köln)
ISSN: 0378-584X (Print), eISSN: 1423-0240 (Online)

For additional information: http://www.karger.com/ONK


Copyright / Drug Dosage

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.